First Trust Advisors LP Immunovant, Inc. Transaction History
First Trust Advisors LP
- $127 Billion
- Q3 2025
Shares
2 transactions
Others Institutions Holding IMVT
# of Institutions
212Shares Held
81MCall Options Held
557KPut Options Held
704K-
Deep Track Capital, LP Greenwich, CT9.73MShares$268 Million8.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.83MShares$188 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.84MShares$161 Million2.47% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.16MShares$142 Million0.05% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...